Add this result to my export selection Ranibizumab for treating diabetic macular oedema (TA274/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2013 Recommendation ID TA274/1 Question NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 July 2013 Recommendation ID TA293/1 Question NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 April 2012 Recommendation ID TA254/1 Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 July 2014 Recommendation ID TA316/1 Question NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 March 2011 Recommendation ID TA217/1 Question Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer's Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 January 2013 Recommendation ID TA272/1 Question Research on second-line treatments for transitional cell carcinoma of the urothelial tract is needed Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2011 Recommendation ID TA216/1 Question Research should be carried out to compare the clinical effectiveness of bendamustine with chlorambucil Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 December 2018 Recommendation ID TA553/1 Question Proposals for further data collection in the Cancer Drugs Fund include:- recurrence-free survival- distant Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287/2) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 June 2013 Recommendation ID TA287/2 Question Research into the long-term treatment effects of rivaroxaban is needed. Any explanatory notes(if Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217/2) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 March 2011 Recommendation ID TA217/2 Question Research is needed on the impact of treating Alzheimer's disease on mortality and institutionalisation Type: Evidence Uncertainties (Remove filter)